Central Nervous System Biomarkers Market 2026 Growth Trends by Manufacturers, Regions, Type and Application, Forecast


Posted February 18, 2019 by coherent123

Biomarkers are measurable indicators used to evaluate and determine pathogenic processes and therapeutic interventions and predict treatment response.

 
Biomarkers are measurable indicators used to evaluate and determine pathogenic processes and therapeutic interventions and predict treatment response. Biomarkers are used in various scientific fields. Biomarkers are utilized in drug development and regulatory decision-making process as they have the potential to improve the efficiency of drug discovery and development process. Biomarkers offer information about a patient at virtually every stage of care. Biomarker development for brain disorders is increasing rapidly with advanced technologies that permit molecular and functional disease measures taken from brain, cerebrospinal fluid (CSF), and plasma.

Central Nervous System Biomarkers Market – Regional Analysis

On the basis of region, the global central nervous system biomarkers market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America central nervous system biomarkers market is expected to show significant growth, owing to expansion activities by key players in the region. For Instance, in January 2017, bioMérieux, an in vitro diagnostics company, entered into a partnership with Banyan Biomarkers. Banyan Biomarkers develops, validate, and market blood-based biomarkers for traumatic brain injury. Under this agreement, bioMérieux  took an equity participation of around US$ 7 million in Banyan Biomarkers and also obtained rights to develop market for Banyan’s proprietary tests worldwide.

Increasing prevalence of Alzheimer’s disease is expected to drive growth for the central nervous system biomarkers market in Asia Pacific. For instance, according to Alzheimer's Disease International (ADI), in 2015, around 23 million people in Asia Pacific suffered from dementia.

Keys players

Thermo fisher scientific, Enzo Biochem Inc., Abiant Inc., EKF Diagnostics Holdings Inc., Abastar MDX Inc., Acumen Pharmaceuticals Inc., Adlyfe Inc., Apitope International, Alseres Pharmaceuticals Inc., Aposense, Banyan Biomarkers, Avid Radiopharmaceuticals Inc., Diagenic ASA, Avacta Group plc., Applied Neurosolutions Inc., Merc & Co. Inc., and Exonhit Therapeutics.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2434

Central Nervous System Biomarkers Market – Taxonomy
By Application
• Drug Discovery & Development
• Personalized Medicines
• Disease Risk Assessment
• Diagnostics
By Disease Indication
• Alzheimer’s Disease
• Multiple Sclerosis
• Parkinson’s Disease
• Traumatic Brain Injury
• Other Neurological Conditions
By End User
• Diagnostic Labs
• Clinics/Hospitals
• Research Centers
By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By COHERENT4484
Country India
Categories Health
Tags central nervous system biomarkers outlook
Last Updated February 18, 2019